Oxaliplatin (Eloxatin) + 5-FU/LV [fluorouracil/folinic acid] (FOLFOX4) compared with single agent doxorubicin (Adriamycin) as palliative chemotherapy in advanced hepatocellular carcinoma patients ineligible for curative resection or local treatment.

Trial Profile

Oxaliplatin (Eloxatin) + 5-FU/LV [fluorouracil/folinic acid] (FOLFOX4) compared with single agent doxorubicin (Adriamycin) as palliative chemotherapy in advanced hepatocellular carcinoma patients ineligible for curative resection or local treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2013

At a glance

  • Drugs Doxorubicin; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EACH
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Aug 2013 Primary endpoint 'Overall-survival-duration' has not been met.
    • 26 Aug 2013 Final results published in the Journal of Clinical Oncology.
    • 12 Oct 2010 Updated results presented at the 35th Congress of the European Society for Medical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top